| Autor: |
Ke Z; Medical Molecular Diagnostics Key Laboratory of Guangdong, Dongguan 523808, China.; Department of Biochemistry and Molecular Biology Guangdong Medical University, Dongguan 523808, China., Liang A; Medical Molecular Diagnostics Key Laboratory of Guangdong, Dongguan 523808, China.; Department of Clinical Laboratory Biochemistry in Guangdong Medical University, Dongguan 523808, China., Liu Y; Medical Molecular Diagnostics Key Laboratory of Guangdong, Dongguan 523808, China.; Department of Biochemistry and Molecular Biology Guangdong Medical University, Dongguan 523808, China. |
| Jazyk: |
čínština |
| Zdroj: |
Zhongguo fei ai za zhi = Chinese journal of lung cancer [Zhongguo Fei Ai Za Zhi] 2021 Apr 20; Vol. 24 (4), pp. 265-270. |
| DOI: |
10.3779/j.issn.1009-3419.2021.101.09 |
| Abstrakt: |
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a class of diseases with damaged cell cycle regulation mechanism, in which checkpoint kinase (Chk) plays a core role, Chk1 and Chk2 are very important protein kinases in the checkpoint. In recent years, it has been found that the regulation of Chk1 and Chk2 plays an important role in the clinical treatment and drug resistance mechanism of lung cancer. This article reviews the mechanism of cell cycle checkpoint kinase and drug resistance of lung cancer, and expounds the effective therapeutic targets and methods of lung cancer.
. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
